

APC anti-mouse CD11c Antibody

| | |
|--------------------------|---|
| Catalog# / Size | 117309 / 25 µg 117310 / 100 µg |
| Clone | N418 |
| Regulatory Status | RUO |
| Other Names | αX integrin, integrin αX chain, CR4, p150, ITGAX |
| Isotype | Armenian Hamster IgG |
| Description | CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54. |

Product Details

| | |
|---|---|
| Verified Reactivity | Mouse |
| Antibody Type | Monoclonal |
| Host Species | Armenian Hamster |
| Immunogen | Mouse spleen dendritic cells |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. |
| Concentration | 0.2 mg/ml |
| Storage & Handling | The CD11c antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. |
| Excitation Laser | Red Laser (633 nm) |
| Application Notes | Additional reported applications (for the relevant formats) include: immunoprecipitation ³ , immunohistochemical staining of acetone-fixed frozen sections ³ , immunofluorescence microscopy ^{5,9} (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections ¹⁰), and spatial biology (IBEX) ^{22,23} . |
| Application References | <ol style="list-style-type: none"> Granucci F, <i>et al.</i> 1997. <i>J. Immunol.</i> 159:1794. Stokes RW, <i>et al.</i> 1998. <i>J. Immunol.</i> 160:5514. Metlay JP, <i>et al.</i> 1990. <i>J. Exp. Med.</i> 171:1753. (IHC, IP) Ma XT, <i>et al.</i> 2006. <i>Cancer Research</i> 66:1169. Chin RK, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:290. (IF) Cervantes-Barragan L, <i>et al.</i> 2007. <i>Blood</i> 109:1131. (FC) PubMed Turnquist HR, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:7018. (FC) PubMed Benson MJ, <i>et al.</i> 2007. <i>J. Exp. Med.</i> doi:10.1084/jem.20070719. (FC) PubMed You Y, <i>et al.</i> 2009. <i>J. Immunol.</i> 182:7343. (IF) PubMed Roland CL, <i>et al.</i> 2009. <i>Mol. Cancer Res.</i> 8:1761. (IHC, FC) PubMed Wikstrom M, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:913. PubMed Pericolini E, <i>et al.</i> 2008. <i>J. Leukocyte Biol.</i> 83:1286. PubMed Randall LM, <i>et al.</i> 2008. <i>Infect. Immun.</i> 76:3312. PubMed Fahlen-Yrild L, <i>et al.</i> 2009. <i>J. Immunol.</i> 183:5032. PubMed |
| (PubMed link indicates BioLegend citation) | |

15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, *et al.* 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Narusawa M, *et al.* 2014. *Cancer Immunol Res.* 2:568. [PubMed](#)
2. Koyama M, *et al.* 2015. *J Exp Med.* 212: 1303 - 1321. [PubMed](#)
3. Lin C, *et al.* 2020. *Cancer Immunol Res.* 632:8. [PubMed](#)
4. Ramakrishna C, *et al.* 2019. *Nat Commun.* 10:2153. [PubMed](#)
5. Tomida S, *et al.* 2019. *Sci Rep.* 9:10751. [PubMed](#)
6. Kawabe T, *et al.* 2020. *Nat Commun.* 2.795833333. [PubMed](#)
7. Garo LP, *et al.* 2021. *Nat Commun.* 12:2419. [PubMed](#)
8. Shah D, *et al.* 2021. *Oncoimmunology.* 10:1939601. [PubMed](#)
9. Zhu Y, *et al.* 2022. *Nat Commun.* 13:4282. [PubMed](#)
10. Minute L, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
11. Miller CM, *et al.* 2020. *J Virol.* 94:00:00. [PubMed](#)
12. Gujar R, *et al.* 2016. *J Immunol.* 197: 1650 - 1662. [PubMed](#)
13. Nocera D, *et al.* 2016. *J Immunol.* 196: 2860 - 2869. [PubMed](#)
14. Riva A, *et al.* 2013. *J Immunol.* 190:5961. [PubMed](#)
15. Zhang LJ, *et al.* 2019. *Immunity.* 50:121. [PubMed](#)
16. Shi L, *et al.* 2019. *Theranostics.* 9:4115. [PubMed](#)
17. Page N, *et al.* 2018. *Immunity.* 48:937. [PubMed](#)
18. Alissafi T, *et al.* 2018. *J Clin Invest.* 128:3840. [PubMed](#)
19. Iwamoto H *et al.* 2018. *Cell metabolism.* 28(1):104-117 . [PubMed](#)
20. Kitai H, *et al.* 2022. *BMC Biol.* 20:248. [PubMed](#)
21. Tan L, *et al.* 2022. *Biochem Biophys Rep.* 32:101351. [PubMed](#)
22. Li Q, *et al.* 2022. *Cell Rep.* 40:111308. [PubMed](#)
23. Lefebvre MN, *et al.* 2021. *Cell Rep.* 37:109956. [PubMed](#)
24. Jiang Q, *et al.* 2022. *Theranostics.* 12:59. [PubMed](#)
25. Zhou J, *et al.* 2021. *Int J Med Sci.* 18:3516. [PubMed](#)
26. Meng W, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
27. Xia S, *et al.* 2014. *J Leukoc Biol.* 95:733. [PubMed](#)
28. Aguilera T, *et al.* 2016. *Nat Commun.* 7:13898. [PubMed](#)
29. Postat J *et al.* 2018. *Immunity.* 49(4):654-665 . [PubMed](#)
30. Kim TJ, *et al.* 2019. *Nat Commun.* 10:3258. [PubMed](#)
31. Takeda Y, *et al.* 2018. *Innate Immun.* 24:323. [PubMed](#)
32. Kunimura K, *et al.* 2020. *Cell Reports.* 29(9):2823-2834.e7.. [PubMed](#)
33. Pandey S, *et al.* 2020. *Cell Syst.* 11:495. [PubMed](#)
34. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 5:64. [PubMed](#)
35. Sauter M, *et al.* 2022. *iScience.* 25:103677. [PubMed](#)
36. Almeida AS, *et al.* 2021. *Bio Protoc.* 11:e4012. [PubMed](#)
37. Nam J, *et al.* 2021. *Adv Sci (Weinh).* 2002577:8. [PubMed](#)
38. de Mingo Pulido , *et al.* 2021. *Immunity.* 54(6):1154-1167.e7. [PubMed](#)
39. Coppo M, *et al.* 2016. *Nat Commun.* 7:12254. [PubMed](#)
40. Wegmann F, *et al.* 2015. *Clin Vaccine Immunol.* 22: 1004-1012. [PubMed](#)
41. Qian F, *et al.* 2015. *J Mol Cell Biol.* . [PubMed](#)
42. He Y, *et al.* 2020. *Sci Adv.* 6:eaba7589. [PubMed](#)
43. Blumenthal D, *et al.* 2020. *eLife.* 9:e55995.. [PubMed](#)
44. Li Y, *et al.* 2020. *Cell Rep.* 30:1753. [PubMed](#)
45. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134 . [PubMed](#)
46. Shin M *et al.* 2019. *Cell Chem Biol.* 26(7):1036-1041 . [PubMed](#)
47. Agelidis A, *et al.* 2019. *Front Immunol.* 10:500. [PubMed](#)
48. Zhao J, *et al.* 2019. *Nat Commun.* 10:899. [PubMed](#)
49. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503 . [PubMed](#)
50. Oyarce C, *et al.* 2018. *Front Immunol.* 8:1794. [PubMed](#)
51. Liang W, *et al.* 2022. *Methods Mol Biol.* 2574:221. [PubMed](#)
52. Wiernicki B, *et al.* 2022. *Nat Commun.* 13:3676. [PubMed](#)
53. Zhou X, *et al.* 2022. *Front Pharmacol.* 13:887263. [PubMed](#)
54. Chen WS, *et al.* 2021. *Cell Rep.* 37:109974. [PubMed](#)
55. Klarquist J, *et al.* 2021. *Cell Rep.* 36:109591. [PubMed](#)
56. Prado C, *et al.* 2012. *J Immunol.* 188:3062. [PubMed](#)
57. Tsuchiya N, *et al.* 2020. *Cell Reports.* 29(1):162-175.e9.. [PubMed](#)
58. Bode K, *et al.* 2020. *Cell Reports.* 29(13):4435-4446.e9. [PubMed](#)
59. Wiede F, *et al.* 2021. *Cancer Discov.* Online ahead of print. [PubMed](#)
60. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
61. Helm M, *et al.* 2022. *Life (Basel).* 12:. [PubMed](#)
62. Xiong A, *et al.* 2022. *EBioMedicine.* 83:104239. [PubMed](#)
63. Yu AI, *et al.* 2020. *Cell Rep.* 107471:31. [PubMed](#)
64. Han C, *et al.* 2021. *Cell Reports.* 34(6):108706. [PubMed](#)
65. O'Shea NR, Chew TS 2016. *J Crohns Colitis.* 10(12):1417-1427. [PubMed](#)
66. Angelidis I, *et al.* 2019. *Nat Commun.* 10:963. [PubMed](#)
67. Cao W, *et al.* 2017. *Immunity.* 47:1182. [PubMed](#)

68. Best SA, *et al.* 2018. *Cell Metab.* 27:935. [PubMed](#)
69. Sharma PK, *et al.* 2018. *Cancer Gene Ther.* 25:27. [PubMed](#)
70. Wang Y, *et al.* 2022. *Front Immunol.* 13:767630. [PubMed](#)
71. Hao F, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
72. Kulkarni NN, *et al.* 2021. *J Biol Chem.* 297:100828. [PubMed](#)
73. Dos Santos Dias L, *et al.* 2021. *PLoS Pathog.* e1009324:17. [PubMed](#)
74. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
75. Fujita Y *et al.* 2018. *Cell reports.* 24(12):3296-3311 . [PubMed](#)
76. Lin SY, *et al.* 2017. *Autophagy.* 14:778. [PubMed](#)
77. Yuan B, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
78. Jing L, *et al.* 2022. *Front Immunol.* 13:864995. [PubMed](#)
79. Almeida AS, *et al.* 2021. *Bio Protoc.* 11:e4012. [PubMed](#)
80. Wang B, *et al.* 2022. *Nat Commun.* 13:3821. [PubMed](#)
81. Marjanovic ND, *et al.* 2020. *Cancer Cell.* 38(2):229-246.e13. [PubMed](#)
82. Wang Y, *et al.* 2021. *Sci Rep.* 1.429861111. [PubMed](#)
83. Sellau J, *et al.* 2016. *Sci Rep.* 6:28058. [PubMed](#)
84. Gereke M, *et al.* 2012. *J Vis Exp.* 70: 4322. [PubMed](#)
85. Madan-Lala R, *et al.* 2014. *J Immunol.* 192:4263. [PubMed](#)
86. Bunn P, *et al.* 2014. *J Immunol.* 192:3709. [PubMed](#)
87. Ustarroz-Cano M, *et al.* 2012. *J Immunotoxicol.* 9:374. [PubMed](#)
88. Bak S, *et al.* 2008. *Mol Immunol.* 45:1414. [PubMed](#)
89. Bertino P, *et al.* 2019. *Oncoimmunology.* 8:1601482. [PubMed](#)
90. Lisk C, *et al.* 2020. *Front Immunol.* 1.329166667. [PubMed](#)
91. Gu H, *et al.* 2018. *Aging (Albany NY).* 1.525694444. [PubMed](#)
92. Varol D *et al.* 2017. *Immunity.* 46(6):1030-1044 . [PubMed](#)
93. Liu D *et al.* 2019. *Immunity.* 51(1):64-76 . [PubMed](#)
94. Matsumura T *et al.* 2019. *Cell Rep.* 27(2):561-571 . [PubMed](#)
95. Mrdjen D *et al.* 2018. *Immunity.* 48(2):380-395 . [PubMed](#)
96. McAlpine CS, *et al.* 2021. *Nature.* 595:701. [PubMed](#)
97. Stump CT, *et al.* 2021. *Open Biol.* 11:210245. [PubMed](#)
98. Dokoshi T, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
99. Glauser D, *et al.* 2013. *J Virol.* 87:10828. [PubMed](#)
100. Aebischer D, *et al.* 2014. *PLoS One.* 9:99297. [PubMed](#)
101. Spinner C, *et al.* 2015. *Sci Rep.* 5:16269. [PubMed](#)
102. Hrdinka M, *et al.* 2016. *PLoS One.* 11: 0162863. [PubMed](#)
103. Li N, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
104. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
105. Gozgit JM, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
106. Kooreman NG *et al.* 2018. *Cell stem cell.* 22(4):501-513 . [PubMed](#)
107. Xu H, *et al.* 2020. *Immunity.* 51(4):696-708.e9.. [PubMed](#)
108. Suryawanshi RK, *et al.* 2021. *Nat Commun.* 12:6020. [PubMed](#)
109. Du Y, *et al.* 2022. *Nat Commun.* 13:231. [PubMed](#)
110. Formaglio P, *et al.* 2021. *Immunity.* 54:2724. [PubMed](#)
111. Cho YK, *et al.* 2022. *Nat Commun.* 13:4084. [PubMed](#)
112. Zou J, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:983. [PubMed](#)
113. Li W, *et al.* 2021. *Front Pharmacol.* 12:697483. [PubMed](#)
114. Mulas F, *et al.* 2020. *Cell Mol Immunol.* . [PubMed](#)
115. Liu M, *et al.* 2016. *PLoS One.* 11:e0166165. [PubMed](#)
116. Markey K, *et al.* 2014. *J Immunol.* 192:5426. [PubMed](#)
117. Cheng Y, *et al.* 2020. *PLoS Pathog.* 16:e1008569. [PubMed](#)
118. Dmitrieva-Posocco O *et al.* 2019. *Immunity.* 50(1):166-180 . [PubMed](#)
119. Yadava K *et al.* 2019. *Elife.* 8 pii: e44821. [PubMed](#)
120. Garo LP, *et al.* 2019. *Cell Rep.* 28:3353. [PubMed](#)
121. Budida R, *et al.* 2017. *Eur J Immunol.* 47:1819. [PubMed](#)
122. Niknam S, *et al.* 2018. *Clin Cancer Res.* 24:5735. [PubMed](#)
123. Miteva K, *et al.* 2018. *Sci Rep.* 8:2820. [PubMed](#)
124. Yang J, *et al.* 2022. *Microbiome.* 10:149. [PubMed](#)
125. Xu M, *et al.* 2022. *Genes Dis.* 9:429. [PubMed](#)
126. Ye P, *et al.* 2022. *Front Cardiovasc Med.* 8:810477. [PubMed](#)
127. Gibbins J, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
128. White C, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
129. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
130. Wanner-Seleznik GM, *et al.* 2020. *Immunohorizons.* 0.644444444. [PubMed](#)
131. Liu Z, *et al.* 2021. *Immunity.* 54(2):247-258.e7. [PubMed](#)
132. Deerhake ME, *et al.* 2021. *Immunity.* 54(3):484-498.e8. [PubMed](#)
133. Zeng W, *et al.* 2021. *STAR Protocols.* 2(1):100361. [PubMed](#)
134. Platteel A, *et al.* 2017. *Vaccine.* 10.1016/j.vaccine.2017.10.044. [PubMed](#)
135. Hu J, *et al.* 2019. *Mol Ther Nucleic Acids.* 16:650. [PubMed](#)
136. He J, *et al.* 2019. *J Clin Invest.* 130. [PubMed](#)
137. Kemp V, *et al.* 2018. *Cancer Gene Ther.* 26:268. [PubMed](#)
138. Kramer K, *et al.* 2017. *ACS Omega.* 0.240972222. [PubMed](#)
139. Liu W, *et al.* 2019. *Epigenetics.* 1.192361111. [PubMed](#)
140. Marsh L, *et al.* 2009. *Am J Physiol Lung Cell Mol Physiol.* 296:L442. [PubMed](#)
141. Yang Y, *et al.* 2021. *Sci Adv.* 7:eabf6290. [PubMed](#)
142. Kim S, *et al.* 2021. *Elife.* 10:. [PubMed](#)
143. Covarrubias AJ, *et al.* 2020. *Nat Metab.* 1265:2. [PubMed](#)
144. Li C, *et al.* 2021. *Cell Metabolism.* 33(8):1610-1623.e5. [PubMed](#)
145. Dobson HE, *et al.* 2020. *Mucosal Immunol.* 0.901388889. [PubMed](#)
146. Lee L, *et al.* 2016. *PLoS One.* 11:e0167693. [PubMed](#)
147. Mainini F, *et al.* 2015. *PLoS One.* 10: 0145403. [PubMed](#)

148. Sakai F, *et al.* 2014. PLoS One. 9:105370. [PubMed](#)
149. Liu Z, *et al.* 2020. Cell. 178(6):1509-1525.e19. [PubMed](#)
150. Yahagi A, *et al.* 2019. RMD Open. 5:e000853. [PubMed](#)
151. Xia P *et al.* 2018. Immunity. 48(4):688-701. [PubMed](#)
152. Nam GH, *et al.* 2018. Nat Commun. 9:2165. [PubMed](#)
153. Lang V, *et al.* 2021. Elife. 10. [PubMed](#)
154. Maulloo CD, *et al.* 2021. Front Immunol. 12:714842. [PubMed](#)
155. Takaki H, *et al.* 2013. J Immunol. 191:4740. [PubMed](#)
156. Wang H, *et al.* 2020. Nat Mater. 1.655555556. [PubMed](#)
157. Ye Y, *et al.* 2017. Sci Immunol. 2:17. [PubMed](#)
158. Zeng J, *et al.* 2018. J Immunol. 200:3407. [PubMed](#)
159. Trinh HKT, *et al.* 2019. J Cell Mol Med. 23:3441. [PubMed](#)
160. Fischer FA, *et al.* 2021. Proc Natl Acad Sci U S A. 118. [PubMed](#)
161. Xiao Y, *et al.* 2022. Nat Commun. 13:758. [PubMed](#)
162. Tukaramrao DB, *et al.* 2021. Cancers (Basel). 13. [PubMed](#)
163. Wüthrich M, *et al.* 2021. MBio. 12:e0201821. [PubMed](#)
164. Schneider KM, *et al.* 2022. Nat Commun. 13:3964. [PubMed](#)
165. Kohn EM, *et al.* 2022. J Immunol. 208:1417. [PubMed](#)
166. Wang Y, *et al.* 2022. J Control Release. 349:118. [PubMed](#)
167. Shan B, *et al.* 2020. Nat Metab. 1332:2. [PubMed](#)
168. Zhao L, *et al.* 2021. STAR Protocols. 2(3):100732. [PubMed](#)
169. Peng X, *et al.* 2016. J Cell Sci. 129: 1831 - 1842. [PubMed](#)
170. Tozuka M, *et al.* 2016. J Dermatol Sci. 82: 38-45. [PubMed](#)
171. Kalafati L, *et al.* 2020. Cell. 183:771. [PubMed](#)
172. Chitu V, *et al.* 2020. Cell Reports. 30(9):3004-3019. [PubMed](#)
173. Burgener SS, *et al.* 2019. Cell Rep. 27:3646. [PubMed](#)
174. Yamada S, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:994. [PubMed](#)
175. Chu LH, *et al.* 2018. Nat Commun. 9:996. [PubMed](#)
176. Tang Z, *et al.* 2021. Stem Cell Res Ther. 12:397. [PubMed](#)
177. Zhang XW, *et al.* 2021. Oncoimmunology. 10:1920739. [PubMed](#)
178. Li X, *et al.* 2021. Cell Death Dis. 12:314. [PubMed](#)
179. Berthold N, *et al.* 2013. Antimicrob Agents Chemother. 57:402. [PubMed](#)
180. Upadhy R, *et al.* 2016. MBio. 7: 00547-16. [PubMed](#)
181. Onai N, *et al.* 2020. Int J Mol Sci. :22. [PubMed](#)
182. Li C, *et al.* 2018. Cell. 174:285. [PubMed](#)
183. Nagashima H *et al.* 2019. Immunity. 51(4):682-695. [PubMed](#)
184. Alexander Mildner *et al.* 2017. Immunity. 46(5):849-862. [PubMed](#)
185. Carlson PM, *et al.* 2021. J Immunol. 207:720. [PubMed](#)
186. Woodring T, *et al.* 2022. iScience. 25:104934. [PubMed](#)
187. Sebina I, *et al.* 2016. PLoS Pathog. 12:e1005999. [PubMed](#)
188. Zhao W, *et al.* 2014. Clin Vaccine Immunol. 21:74. [PubMed](#)
189. McCauley ME, *et al.* 2020. Nature. 585(7823):96-101. [PubMed](#)
190. Qian Z, *et al.* 2022. Biomedicines. 10. [PubMed](#)
191. Bezu L, *et al.* 2022. J Immunother Cancer. 10. [PubMed](#)
192. Huang T, *et al.* 2022. Nat Commun. 13:3489. [PubMed](#)
193. Vogel A, *et al.* 2022. Cell Rep. 38:110420. [PubMed](#)
194. Montes de Oca M, *et al.* 2016. PLoS Pathog. 12: 1005398. [PubMed](#)
195. Singhal P, *et al.* 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. [PubMed](#)
196. Cerina M, *et al.* 2017. Brain Behav Immun. 59:103-117. [PubMed](#)
197. Kramer K, *et al.* 2017. Mol Ther. 25(1):62-70. [PubMed](#)
198. Yin X, *et al.* 2020. Cell Rep. 33:108278. [PubMed](#)
199. Huang WC, *et al.* 2020. Adv Mater. 32:e2005637. [PubMed](#)
200. Sparber F, *et al.* 2019. Cell Host Microbe. 25:389. [PubMed](#)
201. Wang S, *et al.* 2020. J Cell Mol Med. 24:722. [PubMed](#)
202. Dokoshi T, *et al.* 2020. Cell Rep. 30:61. [PubMed](#)
203. Van Den Eeckhout B, *et al.* 2020. NPJ Vaccines. 0.252777778. [PubMed](#)
204. Jiang Y, *et al.* 2021. Nat Commun. 12:742. [PubMed](#)
205. Lisk C, *et al.* 2021. Front Immunol. 12:624197. [PubMed](#)
206. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. [PubMed](#)
207. Takahashi N, *et al.* 2022. Tohoku J Exp Med. 257:171. [PubMed](#)
208. Grube J, *et al.* 2022. Cell Death Dis. 13:704. [PubMed](#)
209. Liu Q, *et al.* 2021. Adv Mater. 33:e2102852. [PubMed](#)
210. Ryu S, *et al.* 2021. eLife. 0.416666666666667. [PubMed](#)
211. Wang Y, *et al.* 2021. Nat Commun. 0.570833333. [PubMed](#)
212. Aguilera TA, *et al.* 2020. Clin Cancer Res. 26:2972. [PubMed](#)
213. Martins R, *et al.* 2016. Nat Immunol. 17:1361-1372. [PubMed](#)
214. Pelly V, *et al.* 2016. Mucosal Immunol. 10.1038/mi.2016.4. [PubMed](#)
215. Huang WC, *et al.* 2020. NPJ Vaccines. 5:23. [PubMed](#)
216. Kunishita Y, *et al.* 2020. Front Immunol. 11:98. [PubMed](#)
217. Wang C, *et al.* 2018. Sci Transl Med. 10. [PubMed](#)
218. Dye BR, *et al.* 2020. Biomaterials. 234:119757. [PubMed](#)
219. Shen H, *et al.* 2022. Nat Commun. 13:5013. [PubMed](#)
220. Smith LK, *et al.* 2021. Elife. 10. [PubMed](#)
221. Harding CL, *et al.* 2020. Front Cell Infect Microbiol. 10:328. [PubMed](#)
222. Li H, *et al.* 2022. iScience. 25:104481. [PubMed](#)
223. Xiao Z, *et al.* 2022. Mater Today Bio. 15:100297. [PubMed](#)
224. Boulch M, *et al.* 2021. Sci Immunol. 6. [PubMed](#)
225. Nicholls J, *et al.* 2021. Front Cell Dev Biol. 9:737880. [PubMed](#)
226. Huang WC, *et al.* 2020. NPJ Vaccines. 5:23. [PubMed](#)
227. Gentschev I, *et al.* 2012. PLoS One. 7:e37239. [PubMed](#)

228. Dyer DP *et al.* 2019. *Immunity*. 50(2):378-389 . [PubMed](#)
 229. Sadtler K, *et al.* 2017. *Tissue Eng Part A*. 23:1044. [PubMed](#)
 230. Matisz CE, *et al.* 2018. *Am J Pathol*. 188:2589. [PubMed](#)
 231. Hong Y, *et al.* 2019. *J Extracell Vesicles*. 8:1670893. [PubMed](#)
 232. Lai NY, *et al.* 2020. *Cell*. 180:33:00. [PubMed](#)
 233. Zhang B, *et al.* 2021. *Nature*. 599:471. [PubMed](#)
 234. Wang X, *et al.* 2021. *Sci Transl Med*. 13:. [PubMed](#)
 235. Spiljar M, *et al.* 2021. *Cell Metab*. 33:2231. [PubMed](#)
 236. Gawish R, *et al.* 2022. *Elife*. 11:. [PubMed](#)
 237. Cortez MA, *et al.* 2020. *Nat Commun*. 3.819444444. [PubMed](#)
 238. Brenner E, *et al.* 2020. *Nat Commun*. 11:1335. [PubMed](#)
 239. Morrissey MA, *et al.* 2018. *Elife*. 7:e36688. [PubMed](#)
 240. Kubli SP, *et al.* 2019. *Nat Commun*. 10:2678. [PubMed](#)
 241. Yáñez A *et al.* 2017. *Immunity*. 47(5):890-902 . [PubMed](#)
 242. Yu L, *et al.* 2022. *Front Immunol*. 13:937331. [PubMed](#)
 243. Sethuraman SN, *et al.* 2020. *Theranostics*. 10:3397. [PubMed](#)
 244. Aggarwal N, *et al.* 2021. *Cell Rep*. 37:110170. [PubMed](#)
 245. Zhong J, *et al.* 2021. *Commun Biol*. 4:865. [PubMed](#)
 246. Akhtar MN, *et al.* 2020. *PLoS Pathog*. 16:e1009136. [PubMed](#)
 247. Shi GN, *et al.* 2021. *Ther Adv Med Oncol*. 13:1758835920987056. [PubMed](#)
 248. Rana MN, *et al.* 2021. *Front Pharmacol*. 12:643215. [PubMed](#)

RRID AB_313778 (BioLegend Cat. No. 117309)
 AB_313779 (BioLegend Cat. No. 117310)

Antigen Details

| | |
|---------------------------|---|
| Structure | Integrin α -chain, associates with integrin β_2 (CD18), 150 kD |
| Distribution | Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells |
| Function | Cellular adhesion |
| Ligand/Receptor | iC3b, fibrinogen |
| Cell Type | Dendritic cells, Epithelial cells, NK cells, T cells, Tregs |
| Biology Area | Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers |
| Molecular Family | Adhesion Molecules, CD Molecules |
| Antigen References | 1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen Facts Book</i> Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol</i> . 156:3780. |
| Gene ID | 16411 |

Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

Product Data

C57BL/6 mouse splenocytes stained
with N418 APC and PK136 PE



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587